Cancer Therapy Advisor

CancerTherapyAdvisor.com is a no-cost online platform designed for oncology healthcare providers. It provides a thorough collection of practical information and clinical tools related to cancer care, helping professionals make informed decisions for their patients.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#401361

United States

#164217

Health/Health Conditions and Concerns

#401

Traffic sources

Monthly visitors

Articles

Chatbot Can Educate Cancer Patients on Genetic Testing and Help Them Access Tests

1 week ago | cancertherapyadvisor.com | Vicki Moore

A chatbot designed to educate cancer patients on genetic testing and help them access tests appears to be effective, according to research presented at the 50th Annual ONS Congress. The chatbot, named Alex, was created using formative research and patient-centered care principles. Refinement of the chatbot occurred through 2 testing phases, involving content-focused user testing and functionality-focused usability testing. Testing involved semi-structured interviews with cancer patients.
How Safe Is Niraparib Maintenance for Ovarian Cancer?

1 week ago | cancertherapyadvisor.com | Victoria Forster

Niraparib maintenance has a tolerable safety profile in patients with ovarian cancer, with hematologic toxicities being “the primary concern,” according to researchers. They evaluated the safety of niraparib in a meta-analysis and reported their results in the European Journal of Obstetrics & Gynecology and Reproductive Biology. The meta-analysis included 8 studies — 4 phase 3 randomized controlled trials (RCTs) and 4 observational studies — published between 2016 and 2024.
Opdivo + Yervoy Approved as First-Line Tx for HCC

1 week ago | cancertherapyadvisor.com | Diana Ernst

The US Food and Drug Administration has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with unresectable or metastatic hepatocellular carcinoma (HCC). The approval was based on results from the phase 3 CheckMate-9DW trial. The trial (NCT04039607) was designed to compare nivolumab plus ipilimumab to investigator’s choice of lenvatinib or sorafenib monotherapy in patients with advanced HCC who had not received prior systemic therapy.
Firings at Federal Health Agencies Decimate Offices That Release Public Records

1 week ago | cancertherapyadvisor.com | Rachana Pradhan |Brett Kelman

Public access to government records that document the handling of illnesses, faulty products, and safety lapses at health facilities will slow after mass firings at the federal Department of Health and Human Services (HHS) swept out staff members responsible for releasing records, according to transparency advocates and health experts. HHS Secretary Robert F.
US Had Second Highest Number of Deaths From Mesothelioma in 2021

2 weeks ago | cancertherapyadvisor.com | Jen Smith

Data suggest that the United States had the second highest number of mesothelioma cases and the second highest number of deaths from mesothelioma in 2021. These data were published in Lung Cancer. For this study, researchers evaluated data from patients in 204 countries and territories who were diagnosed with mesothelioma between 1990 and 2021. The number of mesothelioma cases increased 93.5% over the study period, from 16,493 cases in 1990 to 31,908 cases in 2021.
Some Top-Selling Cancer Drugs May Confer Little or No Therapeutic Benefit

2 weeks ago | cancertherapyadvisor.com | Victoria Forster

New research suggests that most top-selling cancer drugs in the United States provide “high added therapeutic benefits.” However, researchers also found that cancer drugs conferring low or no therapeutic benefits accounted for $6.7 billion in post-rebate Medicare spending in 2022, and these drugs cost more per beneficiary than the drugs that confer high therapeutic benefits. Researchers reported these findings in JAMA Network Open.
Opdivo + Yervoy Approved as First-Line Tx for MSI-H/dMMR Metastatic Colorectal Cancer

2 weeks ago | cancertherapyadvisor.com | Diana Ernst

The US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) as first-line treatment for patients aged 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer (CRC). The approval was supported by data from the phase 3 CHECKMATE-8HW trial. The trial (NCT04008030) enrolled immunotherapy-naïve patients with unresectable or metastatic MSI-H/dMMR CRC.
Factors Driving Worse Survival in Secondary Rectal Cancer

2 weeks ago | cancertherapyadvisor.com | natasha persaud

Patients who develop secondary rectal cancer after receiving radiotherapy for prostate cancer have worse survival outcomes than patients with primary rectal cancer, and several factors may be driving this difference, according to research published in JAMA Network Open. In a case-control study, investigators compared 64 men with secondary rectal cancer (after completing radiotherapy for prostate cancer) and 604 men with primary rectal cancer treated from 1994 to 2022.
Attempts to Slash NIH Funding Continue, Threatening the Future of Scientific Research

2 weeks ago | cancertherapyadvisor.com | Erin Clancy

Researchers and institutions that rely on funding from the National Institutes of Health (NIH) are contending with ongoing efforts by the Trump administration to cut NIH funding, terminate research grants, and reduce the agency’s workforce.1-31 “From what I understand, the environment within NIH is very stressful, with uncertainty about ongoing and future actions from the administration, fear of terminations for staff members or their colleagues, and so on,” said Jeremy Berg, PhD, former...
Many Cancer Patients Afraid of AI in Health Care, Survey Suggests

2 weeks ago | cancertherapyadvisor.com | Vicki Moore

In a survey, 44% of cancer patients said the idea of using artificial intelligence (AI) in health care settings scares them. At the same time, 45% of patients said they can see the benefits of using AI in health care. These and other survey results were presented in a poster at the NCCN Annual Conference 2025. The researchers surveyed 666 patients who participated in the Cancer Experience Registry.